Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer

Human epidermal growth factor receptor-2 (HER2)-targeting drugs are increasingly being incorporated into therapeutic paradigms for non-breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes in OC by reviewing the rec...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-04, Vol.14 (1), p.7992-7992, Article 7992
Main Authors: Kim, Yoo-Na, Chung, Yun Soo, Park, Eunhyang, Lee, Seung Tae, Lee, Jung-Yun
Format: Article
Language:English
Subjects:
631/67/1059/602
631/67/1517/1709
631/67/1857
Biopsy
Breast cancer
Drug delivery
Epidermal growth factor
ErbB-2 protein
Histology
Humanities and Social Sciences
Immunohistochemistry
Mismatch repair
multidisciplinary
Mutation
Mutation rates
Ovarian cancer
Patients
PD-L1 protein
Science
Science (multidisciplinary)
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human epidermal growth factor receptor-2 (HER2)-targeting drugs are increasingly being incorporated into therapeutic paradigms for non-breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes in OC by reviewing the records of patients who underwent HER2 testing at a single institution. Clinical parameters, including histology, BRCA status, and immunohistochemistry (IHC), were evaluated alongside HER2 expression, timing, and anatomical location. Among 200 patients, 28% and 6% exhibited expression scores of 2+ and 3+, respectively. HER2 3+ scores were observed in 23%, 11%, 9%, and 5% of mucinous, endometrioid, clear cell, and high-grade serous tumors, respectively, and were exclusively identified in BRCA -wildtype, mismatch repair-proficient, or PD-L1-low-expressing tumors. The TP53 mutation rate was low, whereas ARID1A, KRAS, and PIK3CA mutations were relatively more prevalent with HER2 scores of 2+ or 3+ than with 0 or 1+. Four of the five tumors with an HER2 3+ score exhibited ERBB2 amplification. Among 19 patients who underwent multiple time-lagged biopsies, 11 showed increased HER2 expression in subsequent biopsies. Patients with HER2-overexpressing OC exhibited distinct histological, IHC, and genomic profiles. HER2-targeting agents are potential options for BRCA -wildtype patients, particularly as later lines of treatment.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-57515-y